BofA raised the firm’s price target on UnitedHealth (UNH) to $350 from $325 and keeps a Neutral rating on the shares. The firm assigns the stock a higher multiple following yesterday’s Medicare Advantage star update and 2025 earnings guidance reiteration. A “stable” stars outlook in 2027 provides better visibility into UnitedHealth’s earnings rebound longer term, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- Mixed options sentiment in UnitedHealth with shares down 1.16%
- Morgan Stanley ‘incrementally positive’ following UnitedHealth discussions
- ‘Recovery on the Horizon,’ Says Morgan Stanley Analyst on UnitedHealth Stock (UNH)
- Positive Outlook and Strategic Initiatives Drive Buy Rating for UnitedHealth
- Why UnitedHealth Stock (UNH) Bulls Are Preparing to Charge